Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q32 Bio Inc. Director's Dealing 2024

Jan 3, 2024

34891_dirs_2024-01-03_bd2648e3-0d78-4c3f-ae62-7ef34b2e0a06.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2024-01-01

Reporting Person: Michaud Charles Jr (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-01-01 Common Stock M 544 Acquired 9610 Direct
2024-01-01 Common Stock M 1056 Acquired 10666 Direct
2024-01-01 Common Stock M 2640 Acquired 13306 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-01-01 Restricted Stock Units $ M 544 Disposed Common Stock (544) Direct
2024-01-01 Restricted Stock Units $ M 1056 Disposed Common Stock (1056) Direct
2024-01-01 Restricted Stock Units $ M 2640 Disposed Common Stock (2640) Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2: The RSUs vested and settled in full on January 1, 2024. The RSUs do not have an expiration date.

F3: The RSUs have vested and settled or will vest and settle as to 1,056 shares on January 1, 2024 and 1,008 shares on January 1, 2025. The RSUs do not have an expiration date.

F4: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026. The RSUs do not have an expiration date.